CL3-95005-006-POL

Research code: CL3-95005-006-POL
Research name: Open, randomised phase III research comparing the use of trifluridine/tipiracil (s 95005) with bevacizumab to capecitabine with bevacizumab in the first-line treatment of patients with metastatic colorectal cancer who are ineligible for intensive treatment (SOLSTICE research).
Indication: colorectal cancer
Principal researcher: Ewa Chmielowska, MD, PhD